Tumour Vasculature-specific Blood Coagulation Induction

4 Tumour Vasculature-specific Blood Coagulation Induction 

Toxins as effector molecules have been widely studied in vitro and applied in vivo in pre-clin-ical and clinical studies. A frequent observation with immunotoxins in the clinic is the occurrence of vascular leak syndrome. This toxicity is associated with the toxin moiety of the im-munotoxin and sometimes demands cessation of therapy or administration of snb-optimal dosages [92]. Another approach with high potential is to selectively inhibit tnmonr blood flow by selectively targeting the blood coagnlation-mdndng activity of the tnmonr endothelium. 

---